R309
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 60
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.690
- MYC_TARGETS_V1+0.480
- E2F_TARGETS+0.460
- G2M_CHECKPOINT+0.370
- PANCREAS_BETA_CELLS+0.260
- GLYCOLYSIS+0.250
- MTORC1_SIGNALING+0.250
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.250
- OXIDATIVE_PHOSPHORYLATION+0.240
- PEROXISOME+0.240
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.480
- INTERFERON_GAMMA_RESPONSE-0.390
- PROTEIN_SECRETION-0.370
- TGF_BETA_SIGNALING-0.310
- ALLOGRAFT_REJECTION-0.280
- PI3K_AKT_MTOR_SIGNALING-0.270
- IL6_JAK_STAT3_SIGNALING-0.260
- COMPLEMENT-0.220
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.190
- INFLAMMATORY_RESPONSE-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8942959 | — | — | 0.880 |
| 2 | AUR-AFUM-TTM1-A-1-1-R-A743-41 | — | E | 0.849 |
| 3 | TCGA-39-5037-01A-01R-1443-07 | — | cohortSQ2 | 0.847 |
| 4 | 43c87798-5762-42c1-b7d8-47fc126fc2d3 | — | — | 0.842 |
| 5 | MNG517 | — | — | 0.837 |
| 6 | TCGA-85-8354-01A-31R-2326-07 | — | cohortSQ2 | 0.832 |
| 7 | C3N-02434 | — | cohortSQ2 | 0.832 |
| 8 | TCGA-66-2781-01A-01R-0851-07 | — | cohortSQ2 | 0.825 |
| 9 | TCGA-56-8304-01A-11R-2326-07 | — | cohortSQ1 | 0.820 |
| 10 | MDT-AP-0412 | Med | Medulloblastoma | 0.820 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.690 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.480 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.460 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.370 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.260 | Cobimetinib | — uncovered |
| GLYCOLYSIS | 0.250 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.250 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.250 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.240 | Remibrutinib | — uncovered |
| PEROXISOME | 0.240 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| HYPOXIA | 0.190 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.170 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.150 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.140 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.130 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.130 | Inavolisib | — uncovered |